ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Factor V Leiden, Heterozygous
Gene/Gene Panel: F5
Context: Adult
Date
Status
Release
Outcomes-Interventions
Notes
2024/03/24
Released
1.4.4
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
System migration to fix the sem versioning
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2024/03/24
Released (Under revision)
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2022/11/21
Released
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5 ⇔ 0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Limited Actionability
2022/03/30
Released (Under revision)
1.4.2
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Internal system migration associated with MONDO name addition.
2022/02/09
Released
1.4.2
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Internal system migration associated with MONDO name addition.
2022/02/09
Released (Under revision)
1.4.1
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
2020/04/28
Released
1.4.1
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
2020/04/28
Released (Under revision)
1.4.0
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.4.0
A
VTE (GroupA)
Assessment for VTE risk factors (GroupA) IN
Pharmacological prophylaxis (GroupA) 5CA
Avoid estrogen-containing compounds that exacerbate VTE risk (GroupA) 8CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.3.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.2.2
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
Internal system migration related to score text replacement from E to N
2018/04/09
Released
1.2.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that exacerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/04/09
Released (Under revision)
1.2.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/03/19
Released
1.2.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 8CB
Pharmacological prophylaxis 5CA
2018/03/19
Released (Under revision)
1.1.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/03/19
Released
1.1.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/03/19
Released (Under revision)
1.0.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2018/01/11
Released
1.0.1
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
2017/10/23
Released
1.0.0
A
VTE
Assessment for VTE risk factors IN
Avoid estrogen-containing compounds that excerbate VTE risk 9CB
Pharmacological prophylaxis 6CA
¤ Powered by BCM's Genboree.